New Paradigms in Chronic Myelogenous Leukemia
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: February 20, 2013
Expiration Date: February 20, 2014
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
The estimated number of newly diagnosed cases of chronic myelogenous leukemia (CML) in the United States in 2012 was 5,430. As a small population cancer, the majority of community oncology physicians and their multidisciplinary health care team members have little real experience treating patients with CML, and their practice improvement focus is frequently drawn to more common forms of malignancies which they regularly treat. Since the availability of tyrosine kinase inhibitor (TKI) therapy, the all-cause annual mortality rate has been significantly reduced. Furthermore, significant improvements continue to be made in areas of monitoring, prognosis and treatment, and management advances are occurring at a rapid pace. With no better illustration of this, just during the time of the development of this educational activity, two new therapeutics for CML were approved by the FDA, a third-generation TKI, ponatinib, as well as a new class of drug, omacetaxine. In addition, NCCN guidelines for CML were updated for a second time in four months with significant changes in their recommendations for the treatment and management of CML.
Dr. Eric Feldman, professor of medicine at the Weill Medical College of Cornell University in New York City, is joined by Dr. Neil Shah, associate professor of hematology/oncology at the University of California, San Francisco, in a case presentation discussion of various treatment and management strategies tailored to the specific patient at various times in the life cycle of the disease.
In a supplemental resource (not required for credit) Dr. Feldman provides an in-depth didactic presentation of current treatment and management strategies for CML and the clinical data that supports these options.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in treating patients with chronic myelogenous leukemia.
Upon completion of this educational activity, participants should be able to:
- Compare and contrast TKI therapy options in the front-line and second-line setting based on clinical trial evidence including efficacy and safety, and recognizing trial limitations
- Recall clinical findings relating to efficacy and safety, as well as trial limitations for agents recently approved for overcoming resistance as well as those that overcome T315l resistance and their mechanism of action
- Recall strategies for appropriate CML patient management throughout all phases of CML including current practice guideline recommendations for treatment response monitoring, timing of mutation analysis, tailoring of therapy, TKI-associated side-effect management, approaches to ensure adherence to therapy, and the role and timing of AHSCT and clinical trial referral
Chronic Myelogenous Leukemia Patient Case Studies − Eric J. Feldman, MD and Neil Shah, MD, PhD
Supplemental Resource (not required for credit): Evolving Principles of CML Management 2012/2013 – Eric J. Feldman, MD
Instructions for Participation and Credit
This activity is eligible for credit through February 20, 2014. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Review the current NCCN Guidelines on CML (version 3.2013)
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates may be printed immediately after successfully completing the post-test and activity evaluation.
Eric J. Feldman, MD
Professor of Medicine
Director of Hematologic Malignancies Service
Director of Bone Marrow Transplant Program
Weill Cornell Medical College
New York, New York
Dr. Eric Feldman received his medical degree from New York Medical College. He completed an internship and residency in medicine, and a fellowship in medical oncology at Westchester County Medical Center, New York. Dr. Feldman is currently professor of medicine at Weill Cornell Medical College in New York where he is also director of Hematologic Malignancies Service and the Bone Marrow Transplant Program.
Dr. Feldman is board certified in internal medicine and medical oncology and holds memberships in the American Society of Hematology and the American Society of Clinical Oncology. He has established a national and international reputation as an expert in leukemia clinical research and patient care. He is also experienced in the care of patients undergoing autologous and allogeneic stem cell transplantation. Dr. Feldman's research efforts have been focused on defining the role of new chemotherapeutic and biotherapeutic agents in the treatment of leukemia and on understanding the biology of leukemic cells as it relates to response to chemotherapy. He has had published more than 100 manuscripts in peer-reviewed journals in the area of the biology and the treatment of leukemia.
Neil P. Shah, MD, PhD
Division of Hematology and Oncology
UCSF School of Medicine
San Francisco, California
Dr. Neil Shah received his PhD in microbiology and molecular genetics at the University of California, Los Angeles (UCLA), and his medical degree from the UCLA School of Medicine. He continued his postdoctoral training at UCLA with an internship and residency in internal medicine, followed by a fellowship in hematology and oncology. Dr. Shah is associate professor, Division of Hematology and Oncology at UCSF School of Medicine; co-leader, Hematopoietic Malignancies Program, UCSF Helen Diller Family Comprehensive Cancer Center; and Edward S. Ageno Distinguished Professor of Hematology/Oncology, UCSF.
Dr. Shah is a diplomate in internal medicine, medical oncology, as well as hematology of the American Board of Internal Medicine. He has authored or co-authored numerous publications largely focused on chronic myeloid leukemia (CML), a disease of the hematopoietic pluripotent stem cell. Dr. Shah’s research interests focus on understanding molecular mechanisms of disease response, resistance and persistence in human CML.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-13-343-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 13-343-305
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Neil Shah has received honoraria as a consultant and grant support related to research activities from ARIAD Pharmaceuticals, Inc., and Bristol-Myers Squibb, as well as honoraria as a consultant from Novartis AG.
Dr. Eric Feldman has disclosed no relevant financial relationships.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Shah and Dr. Feldman have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Shah and Dr. Feldman have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at email@example.com.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Bristol-Myers Squibb
©2013 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.